Obesity-Independent Association between Glycemic Status and the Risk of Hematologic Malignancy: A Nationwide Population-Based Longitudinal Cohort Study

Jihun Kang 1, Sang-Man Jin 2,4,†, Seok Jin Kim 3,*, Dahye Kim 4, Kyungdo Han 5, Su-Min Jeong 6, JiWon Chang 7,8, Sang Youl Rhee 3,†, Taewoong Choi 10 and Dong Wook Shin 7,8,11,*,†

Abstract: There have been conflicting results regarding the association between diabetes and the risk of hematologic malignancies, and its interaction with obesity is unknown. This study determined the risk of hematologic malignancies according to the glycemic status in a population-based study involving health screening 9,774,625 participants. The baseline glycemic status of the participants was categorized into no diabetes, impaired fasting glucose (IFG), newly detected diabetes, diabetes duration <5 years, and diabetes duration ≥5 year groups. The association was independent of obesity. The NHL risk increased with the diabetes duration.

Simple Summary: The present nationwide population-based longitudinal cohort study showed that diabetes was associated with an increased risk of hematologic malignancies independent of obesity. The risk of NHL increased according to the progression of dysglycemia towards a longer diabetes duration, while HL did not.

Received: 7 September 2021
Accepted: 17 September 2021
Published: 23 September 2021
Keywords: hematologic malignancies; Hodgkin’s lymphoma; non-Hodgkin’s lymphoma; diabetes; glycemic status

1. Introduction

Diabetes substantially increases the risk of cardiovascular diseases and mortality. There is also an accumulating body of evidence indicating that diabetes is associated with an increased risk of various solid cancers, including liver [1], endometrial [2], stomach [3], and colorectal cancers [4]. However, there are conflicting results regarding the association between diabetes and hematologic malignancies. Some studies have found that diabetes was associated with an increased risk of HL, while others failed to show an association between these two conditions [5–8]. There have also been conflicting results regarding non-Hodgkin’s lymphoma (NHL). While some studies showed no association between diabetes and NHL [3,5,6,9–11], others [7,12,13] found up to a two-fold higher risk or NHL in diabetes patients (compared to those without diabetes), respectively. Therefore, there has been a lot of heterogeneity in the risk estimates among prior studies. The discrepant results were also observed in myeloid leukemia (ML) and lymphoid leukemia (LL). A positive association between diabetes, ML, and LL was observed in an earlier study [3]. However, others have failed to show a significant association between these conditions [11,14]. The inconsistency of association also existed when the risk for overall leukemia was estimated in previous studies [5–7,9,10,12]. Some studies have also found an increased risk of MM among people with diabetes compared to that in patients without diabetes [3,12], while others have not demonstrated this association [5–7,9,10,14].

The discrepancies among the previous studies can be explained by several limitations in their study designs. First, the glycemic status at the baseline was dichotomously defined in most studies [3,5–7,9,13–16] rather than discriminating patients based on the broad diabetic spectrum, such as normal glucose tolerance, prediabetes, and diabetes with shorter and longer durations. Therefore, this dichotomous designation prevented prior studies from analyzing the dose-response association between exposure to dysglycemia and the risk of hematologic malignancies. Importantly, the dichotomous definition of diabetes without consideration of disease duration could also result in surveillance bias, because frequent screening and healthcare contacts are likely to happen in the first few years of a diabetes diagnosis. Second, some of the previous studies identified diabetes based on self-reports [6,16]. However, undiagnosed diabetes comprises a substantial proportion of the diabetes population. Third, potential confounders, such as alcohol, smoking, and body mass index, were not adjusted for in the majority of the previous studies [3,7,9,12,15]. Furthermore, to our knowledge, the vast majority of the previous studies included limited numbers of nonobese people with diabetes, because there has been only limited data in the Asian population, except the few studies conducted in China [9,13,15].

The present nationwide population-based longitudinal cohort study determined the risk of overall and specific hematologic malignancies according to the baseline glucose tolerance status and diabetes disease duration after adjusting for potential confounders, including the BMI. To avoid surveillance bias, the study was conducted in those who participated in the universal national health screening program, which has been designed to represent the entire general population in Korea, where the proportion of nonobese type 2 diabetes among the diabetes population is relatively high.

2. Materials and Methods

2.1. Data Source and Study Participants

The present study used the Korean National Health Insurance Services (KNHIS) database. The KNHIS is a universal healthcare program that covers 97% of the entire Korean population. The remaining 3% is covered by the Medicaid program. The KNHIS biennially provides a national health screening program for all Korean employees aged ≥20
and individuals aged ≥40, regardless of their employment status. This nationwide health examination comprises anthropometric indices; biochemical tests; and a questionnaire regarding health behaviors (such as alcohol consumption, smoking status, and physical activity). We identified 10,490,491 individuals who participated in this screening program in 2009. Among them, we excluded 715,866 participants for the following reasons: previous cancer diagnosis (N = 152,872); missing data (N = 547,526); development of a hematologic malignancy (N = 1480), or death (N = 13,988) within 1 year of enrollment. Therefore, a total of 9,774,625 participants were ultimately included in the analysis (Figure 1). The study protocol was approved by the Institutional Review Board of Samsung Medical Center (SMC 2018-08-112). Informed consent was waived, because anonymized and deidentified data were used.

### Figure 1. Flowchart of the study protocol and participants. IFG, impaired fasting glucose.

#### 2.2. Definition of Diabetes and Glucose Tolerance Status

The definition of diabetes was defined by one or more of the following: the presence of the diagnosis codes E11.x–E14.x from the 10th revision of the International Statistical Classification of Diseases (ICD-10), prescription(s) of oral and/or injectable antidiabetic medications, or a fasting plasma glucose ≥ 126 mg/dL [17] during the national health screening program. This definition of diabetes has been described elsewhere [18]. Impaired fasting glucose (IFG) was defined as a fasting glucose level of 100–125 mg/dL [17]. Based on their glycemic status, the participants were categorized into five groups, as follows: no diabetes (fasting plasma glucose <100 mg/dL), IFG (fasting glucose 100–125 mg/dL), newly detected diabetes, diabetes duration <5 year, and diabetes duration ≥5 year [18]. Their glycemic status during the 2009 national health screening was defined as the baseline glycemic status.

#### 2.3. Definition of Hematologic Malignancies

The primary outcome was incident hematologic cancer. The incidence of hematologic malignancies was identified using the registered diagnosis code from the 10th revision of the International Statistical Classification of Diseases (ICD-10), as defined in our previous study [19]: HL (C810); NHL (Diffuse Large B-cell lymphoma (C83.3) and follicular lymphoma (C82)); ML (chronic myeloid leukemia (C92.1) and acute myeloid leukemia (C92.0, C92.5, C92.4, C92.6, C93.0, C94.0, and C94.2)); LL (chronic lymphocytic leukemia...
(C91.1) and acute lymphocytic leukemia (C91.0)); and MM (C90.0). We also matched the code-based diagnosis with registration to the critical disease copayment reduction program to ensure the accuracy of the cancer diagnosis (since patients can only be registered in this program if they have been diagnosed with cancer by a physician). We followed the participants from the day of health screening in 2009 to the date of a hematologic malignancy diagnosis, death from any cause, or 31 December 2017, whichever came first.

2.4. Covariates

The smoking status was categorized into the following three groups: current, ex-, and nonsmokers. Alcohol consumption was categorized into none, mild (1–29 g/day), and heavy intake (≥30 g/day). Regular physical activity was defined as strenuous exercise ≥1 session/week for at least 20 minutes per occasion. The body mass index (BMI) was calculated by kg/m². Hypertension and dyslipidemia were defined by the anthropometric results (blood pressure ≥140 mmHg or total cholesterol ≥240 mg/dL) or ICD-10 codes (I10-I13 and I15 or E78) associated with the relevant medications (antihypertensive or lipid-lowering agents).

2.5. Statistical Analysis

The baseline characteristics of the study participants (among the five groups) were compared using the chi-square test for categorical variables and the analysis of variance (ANOVA) for continuous variables. We calculated the incidence rate of the hematologic malignancies as the total incident cases divided by 100,000 person-years (P-y). The risk of hematologic malignancies was evaluated using a Cox regression analysis. The covariates were adjusted as follows: Model 1 was adjusted for age and sex; Model 2 was additionally adjusted for the smoking status, alcohol consumption, physical activity, and BMI. A stratified analysis was conducted to explore the effect modification by age and BMI. Separate regressions for each age and BMI group were performed. We also tested the p for interactions by inserting the interaction term (age/BMI × glycemic status) with the age/BMI and the glycemic status in the analysis models. Several sensitivity analyses were conducted: (1) including patients who developed hematologic malignancy (N = 1480) or death (N = 13,988) within 1 year of enrollment to reduce the chance of reverse causality, (2) limiting the patients to a subgroup of newly diagnosed diabetes patients to test whether the risk of hematologic malignancies was rapidly elevated in the first year of a diabetes diagnosis, and (3) additionally adjusting diabetes medications to estimate the effect of these medications on the risk of hematologic malignancies among diabetes patients. The statistical analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). Two-tailed p-values < 0.05 were considered statistically significant.

3. Results

The baseline characteristics of the study participants are described in Table 1. During the median follow-up of 7.3 years (interquartile range 7.1–7.6 year), 14,733 hematologic cancers were developed. Among these malignancies, there were 694 cases of HL, 5492 cases of NHL, 4269 cases of ML, 1212 cases of LL, and 3615 cases of MM.

Table 1. Baseline characteristics of the study participants.

| Glycemic Status Category | Normoglycemia | IFG | Newly Detected Diabetes | Diabetes < 5 Years | Diabetes ≥ 5 Years |
|--------------------------|--------------|-----|-------------------------|--------------------|-------------------|
|                          | (n = 6,721,016) | (n = 2,210,782) | (n = 286,721) | (n = 289,846) | (n = 266,260) |
| Age                      | 44.82 ± 13.84 | 49.63 ± 13.27 | 51.85 ± 12.66 | 58.31 ± 11.09 | 61.89 ± 9.89 |
| Sex, male                | 3,471,338 (51.7) | 1,370,671 (62.0) | 204,232 (71.2) | 168,676 (58.2) | 145,231 (54.5) |
| Smoking status           |              |                |                |                  |                  |
| Non-smoker               | 4,131,803 (61.5) | 1,205,511 (54.5) | 133,656 (46.6) | 167,006 (57.6) | 167,597 (62.9) |
| Ex-smoker                | 852,248 (12.7) | 385,137 (17.4) | 52,303 (18.2) | 53,932 (18.6) | 47,252 (17.8) |
Table 1. Cont.

| Glycemic Status Category | Normoglycemia | IFG | Newly Detected Diabetes | Diabetes < 5 Years | Diabetes ≥ 5 Years |
|--------------------------|---------------|-----|-------------------------|-------------------|------------------|
| Current-smoker           | 1,736,965 (25.8) | 620,134 (28.1) | 100,762 (35.1) | 68,908 (23.8) | 51,411 (19.3) |
| Alcohol consumption      |               |     |                         |                   |                  |
| None                     | 3,483,838 (51.8) | 1,041,566 (47.1) | 123,167 (43.0) | 175,294 (60.5) | 178,196 (66.9) |
| Mild                     | 2,772,531 (41.3) | 935,802 (42.3) | 122,823 (42.8) | 88,405 (30.5) | 69,817 (26.2) |
| Heavy                    | 464,647 (6.9) | 233,414 (10.6) | 40,731 (14.2) | 26,147 (9.0) | 18,247 (6.9) |
| Regular physical activity| 1,161,028 (17.3) | 419,581 (19.0) | 54,394 (19.0) | 64,325 (22.2) | 64,782 (24.3) |
| Comorbidities            |               |     |                         |                   |                  |
| Hypertension             | 1,289,796 (19.2) | 726,690 (32.9) | 124,915 (43.6) | 180,358 (62.2) | 177,685 (66.7) |
| Dyslipidemia             | 938,118 (14.0) | 495,844 (22.4) | 81,959 (28.6) | 140,205 (48.4) | 125,602 (47.2) |
| Chronic kidney disease   | 326,778 (4.86) | 147,030 (6.65) | 21,675 (7.56) | 31,530 (10.88) | 45,848 (17.22) |
| Obesity (BMI > 25 kg/m²) | 1,860,854 (27.7) | 875,575 (39.6) | 137,675 (48.0) | 150,114 (51.8) | 114,271 (42.9) |
| Body mass index, kg/m²   | 23.1 (21.1–25.3) | 24.2 (22.2–26.3) | 24.9 (22.8–27.0) | 25.2 (23.2–27.3) | 24.5 (22.6–26.5) |
| Waist circumference, cm  | 79 (72–85) | 82 (76–88) | 85 (80–90) | 86 (81–91) | 85 (80–90) |
| Fasting glucose, mg/dL   | 88 (82–94) | 106 (102–112) | 140 (131–159) | 126 (107–153) | 135 (112–169) |
| Systolic blood pressure, mmHg | 120 (110–130) | 125 (116–135) | 130 (120–139) | 130 (120–138) | 130 (120–139) |
| Diastolic blood pressure, mmHg | 75 (70–80) | 80 (70–84) | 80 (73–88) | 80 (70–85) | 80 (70–83) |
| Total cholesterol, mg/dL | 190 (168–214) | 199 (176–225) | 205 (179–233) | 192 (166–221) | 185 (160–213) |
| Triglycerides, mg/dL     | 105.4 (105.4–105.4) | 128.6 (128.5–128.7) | 162.1 (161.8–162.5) | 150.5 (150.2–150.8) | 139.7 (139.4–140.0) |
| HDL-cholesterol, mg/dL   | 54 (46–64) | 53 (45–62) | 51 (43–60) | 49 (41–58) | 49 (41–57) |
| LDL-cholesterol, mg/dL   | 110 (90–132) | 116 (94–139) | 115 (91–141) | 108 (83–133) | 104 (81–128) |
| Sulfonlurea               |                   |                      |                  |                   |                  |
| Metformin                | 203,200 (70.1) | 224,755 (84.4) |                  |                   |                  |
| Meglitinides             | 10,024 (3.5) | 14,888 (5.6) |                  |                   |                  |
| Thiazolidinedione        | 31,763 (11.0) | 40,912 (15.4) |                  |                   |                  |
| Dipeptidyl peptidase-4 inhibitor | 26,015 (9.0) | 23,424 (8.8) |                  |                   |                  |
| Alpha-glucosidase inhibitor | 39,788 (13.7) | 79,722 (29.9) |                  |                   |                  |
| Insulin                  | 23,523 (8.1) | 47,469 (17.8) |                  |                   |                  |

Data were presented as the numbers (%) or means (95% confidence interval). IFG, impaired fasting glucose; BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein.
3.1. Risk of Hematologic Malignancies According to the Presence of Diabetes

The incidence rates for all the hematologic malignancies with and without diabetes were 35.2 and 19.4 per 100,000 person-year, respectively, with an adjusted hazard ratio (aHR) 1.05 (95% CI (1.01–1.10). The presence of diabetes was associated with a higher risk for HL (aHR 1.28, 95% CI 1.03–1.59) and NHL (aHR 1.09, 95% CI 1.01–1.17) compared to that in the no diabetes group. There was no significant difference in ML (aHR 1.06, 95% CI 0.97–1.16), LL (aHR 1.01, 95% CI 0.85–1.20), or MM (aHR 0.99, 95% CI 0.90–1.08) risks between the two groups (Table 2).

### Table 2. The risk of hematologic malignancies among the participants with diabetes.

| Subjects (N) | Event (n) | Duration (Person-Years) | Incidence Rate (per 100,000 Person-Years) | Model 1 | Model 2 |
|-------------|----------|-------------------------|------------------------------------------|---------|---------|
|             |          |                         |                                          |         |         |
| All Hematologic Malignancy |          |                         |                                          |         |         |
| No Diabetes | 8,931,798| 12,632                  | 65,014,611.6                             | 19.40   | 1 (Ref.)|
| Diabetes    | 842,827  | 2101                    | 5,974,211.7                              | 35.20   | 1.05 (1.01,1.10) |
| 1. Hodgkin Lymphoma |          |                         |                                          |         |         |
| No Diabetes | 8,931,798| 592                     | 65,041,866.8                             | 0.91    | 1 (Ref.)|
| Diabetes    | 842,827  | 102                     | 5,978,296.2                              | 1.71    | 1.27 (1.02,1.58) |
| 2. Non-Hodgkin Lymphoma |          |                         |                                          |         |         |
| No Diabetes | 8,931,798| 4691                    | 65,031,545.4                             | 7.21    | 1 (Ref.)|
| Diabetes    | 842,827  | 801                     | 5,976,673.7                              | 13.40   | 1.11 (1.03,1.20) |
| 3. Myeloid Leukemia |          |                         |                                          |         |         |
| No Diabetes | 8,931,798| 3698                    | 65,035,921.5                             | 5.69    | 1 (Ref.)|
| Diabetes    | 842,827  | 571                     | 5,977,584.1                              | 9.55    | 1.09 (1.00,1.19) |
| 4. Lymphoid Leukemia |          |                         |                                          |         |         |
| No Diabetes | 8,931,798| 1059                    | 65,041,338.5                             | 1.63    | 1 (Ref.)|
| Diabetes    | 842,827  | 153                     | 5,978,245.5                              | 2.56    | 1.04 (0.87,1.23) |
| 5. Multiple Myeloma |          |                         |                                          |         |         |
| No Diabetes | 8,931,798| 3,067                   | 65,037,282.2                             | 4.72    | 1 (Ref.)|
| Diabetes    | 842,827  | 548                     | 5,977,526.9                              | 9.17    | 1.01 (0.92,1.10) |

Model 1 was adjusted for age and sex. Model 2 was additionally adjusted for age, sex, smoking, drinking, physical activity, and body mass index.

3.2. Risk of Hematologic Malignancies According to Baseline Glucose Tolerance Status and Diabetes Duration

The incidence rates of all hematologic malignancies were 18.1, 23.4, 26.5, 35.7, and 43.9 for the no diabetes, IFG, newly detected diabetes, diabetes < 5 year, and diabetes ≥ 5 year groups, with aHRs (95% CI) of 0.99 (0.95–1.02), 0.99 (0.91–1.08), 1.03 (0.96–1.11), and 1.11 (1.03–1.20), respectively.

The risk of HL was significantly higher in the diabetes < 5 year group (aHR 1.51, 95% CI 1.09–2.09) than it was in the no diabetes group but not in the diabetes ≥ 5 year group (aHR 1.27, 95% CI 0.89–1.81). The risk of NHL was significantly higher in the diabetes ≥ 5 year group (aHR 1.24, 95% CI 1.10–1.39) than it was in the no diabetes group. The cumulative incidences of HL and NHL according to the glucose tolerance status is shown in Figure 2. There were no significant differences in the risk of MM, LL, and ML based on the baseline glycemic status (Table 3).
Table 3. The risk of hematologic malignancies according to the glycemic status and diabetes duration.

| Subjects (N)          | Event (n) | Duration (Person-Years) | Incidence Rate (per 1000 Person-Years) | Model 1                  | Model 2                  |
|-----------------------|-----------|-------------------------|----------------------------------------|--------------------------|--------------------------|
| All Hematologic Malignancy |           |                         |                                        |                          |                          |
| Normoglycemia         | 6,721,016 | 8885                    | 48,998,241.0                           | 18.13                    | 1 (Ref.)                 | 1 (Ref.)                 |
| Impaired fasting glucose | 2,210,782 | 3747                    | 16,016,370.5                           | 23.40                    | 1.00 (0.96,1.04)         | 0.99 (0.95,1.02)         |
| Newly detected diabetes | 286,721   | 3747                    | 16,016,370.5                           | 23.40                    | 1.00 (0.96,1.04)         | 0.99 (0.95,1.02)         |
| Diabetes (<5 years)   | 289,846   | 740                     | 2,067,385.4                            | 35.79                    | 1.07 (0.99,1.15)         | 1.03 (0.96,1.11)         |
| Diabetes (≥5 years)   | 266,260   | 818                     | 1,860,258.4                            | 43.97                    | 1.14 (1.06,1.23)         | 1.11 (1.03,1.20)         |

1. Hodgkin’s Lymphoma

| Subjects (N)          | Event (n) | Duration (Person-Years) | Incidence Rate (per 1000 Person-Years) | Model 1                  | Model 2                  |
|-----------------------|-----------|-------------------------|----------------------------------------|--------------------------|--------------------------|
| Normoglycemia         | 6,721,016 | 422                     | 49,017,433.3                           | 0.86                     | 1 (Ref.)                 | 1 (Ref.)                 |
| Impaired fasting glucose | 2,210,782 | 3747                    | 16,024,433.5                           | 1.06                     | 1 (0.84,1.20)           | 1.02 (0.85,1.22)         |
| Newly detected diabetes | 286,721   | 740                     | 2,067,385.4                            | 1.22                     | 1.03 (0.69,1.54)         | 1.04 (0.69,1.57)         |

2. Non-Hodgkin’s Lymphoma

| Subjects (N)          | Event (n) | Duration (Person-Years) | Incidence Rate (per 1000 Person-Years) | Model 1                  | Model 2                  |
|-----------------------|-----------|-------------------------|----------------------------------------|--------------------------|--------------------------|
| Normoglycemia         | 6,721,016 | 3239                    | 49,010,295.7                           | 6.61                     | 1 (Ref.)                 | 1 (Ref.)                 |
| Impaired fasting glucose | 2,210,782 | 1452                    | 16,021,249.7                           | 9.06                     | 1.07 (1.00,1.14)         | 1.05 (0.98,1.12)         |
| Newly detected diabetes | 286,721   | 191                     | 2,047,292.1                            | 9.33                     | 0.98 (0.84,1.13)         | 0.95 (0.82,1.11)         |
| Diabetes (<5 years)   | 289,846   | 282                     | 2,068,219.3                            | 13.64                    | 1.13 (1.00,1.28)         | 1.09 (0.96,1.23)         |
| Diabetes (≥5 years)   | 266,260   | 328                     | 1,861,162.3                            | 17.62                    | 1.27 (1.13,1.43)         | 1.24 (1.10,1.39)         |

3. Myeloid Leukemia

| Subjects (N)          | Event (n) | Duration (Person-Years) | Incidence Rate (per 1000 Person-Years) | Model 1                  | Model 2                  |
|-----------------------|-----------|-------------------------|----------------------------------------|--------------------------|--------------------------|
| Normoglycemia         | 6,721,016 | 2667                    | 49,013,083.3                           | 5.44                     | 1 (Ref.)                 | 1 (Ref.)                 |
| Impaired fasting glucose | 2,210,782 | 1031                    | 16,022,838.2                           | 6.44                     | 0.95 (0.88,1.02)         | 0.93 (0.86,1.00)         |
| Newly detected diabetes | 286,721   | 150                     | 2,047,485.0                            | 7.33                     | 0.97 (0.82,1.15)         | 0.94 (0.80,1.11)         |
| Diabetes (<5 years)   | 289,846   | 197                     | 2,068,637.3                            | 9.52                     | 1.05 (0.91,1.21)         | 1.00 (0.86,1.16)         |
| Diabetes (≥5 years)   | 266,260   | 224                     | 1,861,461.8                            | 12.03                    | 1.18 (1.03,1.36)         | 1.14 (0.99,1.31)         |
### Table 3. Cont.

| Subjects (N) | Event (n) | Duration (Person-Years) | Incidence Rate (per 1000 Person-Years) | Model 1 | Model 2 |
|--------------|-----------|-------------------------|----------------------------------------|---------|---------|
| **4. Lymphoid leukemia**                        |            |                         |                                        |         |         |
| Normoglycemia | 6,721,016  | 746                     | 49,017,148.6                          | 1.52    | 1 (Ref.)| 1 (Ref.)|
| Impaired fasting glucose | 2,210,782  | 313                     | 16,024,189.8                          | 1.95    | 1.1 (0.92, 1.19) | 1.02 (0.90, 1.17) |
| Newly detected diabetes | 286,721    | 45                      | 2,047,662.3                           | 2.20    | 1.07 (0.79, 1.44) | 1.04 (0.77, 1.40) |
| Diabetes (<5 years) | 289,846    | 54                      | 2,068,839.1                           | 2.61    | 1.05 (0.79, 1.39) | 1.01 (0.76, 1.33) |
| Diabetes (≥5 years) | 266,260    | 54                      | 1,861,744.1                           | 2.90    | 1.04 (0.79, 1.38) | 1.02 (0.77, 1.35) |
| **5. Multiple Myeloma**                        |            |                         |                                        |         |         |
| Normoglycemia | 6,721,016  | 2142                    | 49,014,251.6                          | 4.37    | 1 (Ref.)| 1 (Ref.)|
| Impaired fasting glucose | 2,210,782  | 925                     | 16,023,030.6                          | 5.77    | 0.96 (0.89, 1.04) | 0.96 (0.89, 1.04) |
| Newly detected diabetes | 286,721    | 144                     | 2,047,492.8                           | 7.03    | 1.03 (0.87, 1.21) | 1.02 (0.86, 1.21) |
| Diabetes (<5 years) | 289,846    | 199                     | 2,068,565.9                           | 9.62    | 1.01 (0.87, 1.17) | 0.98 (0.85, 1.14) |
| Diabetes (≥5 years) | 266,260    | 205                     | 1,861,468.3                           | 11.01   | 0.96 (0.83, 1.11) | 0.93 (0.81, 1.08) |

Model 1 was adjusted for age and sex. Model 2 was additionally adjusted for age, sex, smoking, drinking, physical activity, and body mass index.

3.3. Glycemic Status and Risk of Hematologic Malignancies Stratified by Age and BMI

There was a significant interaction with age, but not with BMI, in the association between the glycemic status and the risk of all hematologic malignancies (Table 4). The significant interaction with age in the association between the glycemic status and the risk of all hematologic malignancies was attributable to the significant association between the diabetes <5 year (aHR 1.23, 95% CI 1.04–1.44) and diabetes ≥ 5 year groups (aHR 1.26, 95% CI 1.06–1.50) and the risk of NHL in the participants with ages 40–64 years and a small but significant association between the diabetes ≥ 5 year group and the risk of ML in the participants with ages < 40 years (aHR 6.06, 95% CI 2.5–68).

3.4. Sensitivity Analyses

We conducted an analysis including individuals diagnosed with hematologic malignancies within 1 year (n = 1480) and death within 1 year (n = 13,988), and the results were similar to those of our main analysis (Tables S1 and S2). Furthermore, the sensitivity analysis including only newly diagnosed diabetes in the 2009 screening showed no abrupt increase in incidence of the overall hematologic malignancy, HL, or NHL during the first year of a diabetes diagnosis (Figure S1). Finally, subgroup analyses with diabetes patients showed that further adjustments of diabetes medications did not change the associations (Table S3).
### Table 4. Diabetes and glycemic status and risk of hematologic malignancies stratified by age and the body mass index (BMI).

| Age | Diabetes | Glycemic status | N | Blood Cancer | Event | Hodgkin Lymphoma | aHR (95% CI) | Non-Hodgkin Lymphoma | Event | Myeloid Leukemia | Event | Lymphoid Leukemia | Event | Multiple Myeloma | Event | p for interaction |
|-----|----------|-----------------|---|--------------|-------|------------------|--------------|----------------------|-------|-----------------|-------|-----------------|-------|-----------------|-------|------------------|
| <40 | No | No | 3,035,864 | 1446 | 1 (Ref.) | 132 | 1 (Ref.) | 521 | 1 (Ref.) | 604 | 1 (Ref.) | 162 | 1 (Ref.) | 76 | 1 (Ref.) |
| Yes | Yes | 63,404 | 45 | 1.26 (0.94,1.70) | 3 | 1.15 (0.36,3.65) | 12 | 0.93 (0.52,1.65) | 24 | 1.56 (1.03,2.35) | 4 | 1.06 (0.39,2.88) | 3 | 1.45 (0.45,4.65) |
| 40–64 | No | No | 4,880,306 | 7197 | 1 (Ref.) | 313 | 1 (Ref.) | 2711 | 1 (Ref.) | 2109 | 1 (Ref.) | 633 | 1 (Ref.) | 1729 | 1 (Ref.) |
| Yes | Yes | 5,28,531 | 1104 | 1.10 (1.03,1.17) | 56 | 1.25 (0.93,1.67) | 430 | 1.15 (1.04,1.28) | 308 | 1.09 (0.96,1.23) | 86 | 1.02 (0.81,1.28) | 266 | 1.01 (0.89,1.16) |
| ≥65 | No | No | 1,000,628 | 3989 | 1 (Ref.) | 147 | 1 (Ref.) | 1459 | 1 (Ref.) | 985 | 1 (Ref.) | 264 | 1 (Ref.) | 1262 | 1 (Ref.) |
| Yes | Yes | 250,892 | 952 | 0.96 (0.89,1.03) | 43 | 1.22 (0.86,1.71) | 359 | 0.98 (0.87,1.10) | 239 | 0.97 (0.84,1.12) | 63 | 0.97 (0.73,1.28) | 279 | 0.90 (0.79,1.13) |
| p for interaction | N | 0.004 | 0.706 | 0.078 | 0.093 | 0.896 | 0.154 |

### p for interaction

| BMI, kg/m² | Diabetes | Glycemic status | N | Blood Cancer | Event | Hodgkin Lymphoma | aHR (95% CI) | Non-Hodgkin Lymphoma | Event | Myeloid Leukemia | Event | Lymphoid Leukemia | Event | Multiple Myeloma | Event | p for interaction |
|------------|----------|-----------------|---|--------------|-------|------------------|--------------|----------------------|-------|-----------------|-------|-----------------|-------|-----------------|-------|------------------|
| <25 | No | No | 6,195,369 | 8174 | 1 (Ref.) | 396 | 1 (Ref.) | 2995 | 1 (Ref.) | 2380 | 1 (Ref.) | 680 | 1 (Ref.) | 2025 | 1 (Ref.) |
| Yes | Yes | 2,736,429 | 1092 | 1.07 (1.00,1.14) | 55 | 1.29 (0.97,1.72) | 409 | 1.11 (1.00,1.23) | 282 | 1.03 (0.91,1.17) | 89 | 1.18 (0.94,1.48) | 294 | 1.00 (0.88,1.13) |
| ≥25 | No | No | 4,402,060 | 1009 | 1.05 (0.98,1.13) | 47 | 1.22 (0.88,1.70) | 392 | 1.07 (0.96,1.20) | 289 | 1.12 (0.99,1.28) | 64 | 0.86 (0.65,1.12) | 254 | 1.00 (0.87,1.15) |
| p for interaction | N | 0.001 | 0.977 | 0.227 | 0.008 | 0.51 | 0.368 |

### p for interaction

| Glycemic status | BMI, kg/m² | Diabetes | Glycemic status | N | Blood Cancer | Event | Hodgkin Lymphoma | aHR (95% CI) | Non-Hodgkin Lymphoma | Event | Myeloid Leukemia | Event | Lymphoid Leukemia | Event | Multiple Myeloma | Event | p for interaction |
|----------------|------------|----------|-----------------|---|--------------|-------|------------------|--------------|----------------------|-------|-----------------|-------|-----------------|-------|-----------------|-------|------------------|
| <25 | No | No | 4,860,162 | 5990 | 1 (Ref.) | 288 | 1 (Ref.) | 2148 | 1 (Ref.) | 1789 | 1 (Ref.) | 504 | 1 (Ref.) | 1477 | 1 (Ref.) |
| Yes | Yes | 1,335,207 | 2184 | 1.00 (0.95,1.05) | 108 | 1.09 (0.87,1.37) | 847 | 1.09 (1.00,1.18) | 591 | 0.94 (0.85,1.03) | 176 | 1.01 (0.85,1.20) | 548 | 0.95 (0.86,1.05) |
| ≥25 | No | No | 149,046 | 275 | 0.97 (0.86,1.10) | 13 | 1.03 (0.59,1.80) | 86 | 0.86 (0.69,1.07) | 72 | 0.90 (0.71,1.13) | 33 | 1.51 (1.06,2.15) | 77 | 1.05 (0.80,1.36) |
| Yes | Yes | 139,732 | 351 | 1.04 (0.94,1.16) | 22 | 1.64 (1.05,2.54) | 137 | 1.16 (0.97,1.38) | 83 | 0.91 (0.73,1.14) | 23 | 0.93 (0.61,1.42) | 100 | 1.01 (0.82,1.23) |
Table 4. Cont.

|            | N       | All Blood Cancer Event | Hodgkin Lymphoma Event | Non-Hodgkin Lymphoma Event | Myeloid Leukemia Event | Lymphoid Leukemia Event | Multiple Myeloma Event |
|------------|---------|------------------------|------------------------|---------------------------|------------------------|------------------------|------------------------|
| Age        |         |                        |                        |                           |                        |                        |                        |
| ≥25        |         |                        |                        |                           |                        |                        |                        |
| Diabetes ≥ 5 y | 151,989 | 466                    | 1.16 (1.05,1.28)       | 20                        | 1.31 (0.82,2.07)       | 186                    | 1.32 (1.13,1.54)       | 127                    | 1.19 (0.99,1.43)       | 33                     | 1.14 (0.80,1.63)       | 117                    | 0.95 (0.78,1.15)       |
| Normoglycemia | 1,860,854 | 2895                  | 1 (Ref.)               | 134                       | 1 (Ref.)               | 1091                   | 1 (Ref.)               | 878                    | 1 (Ref.)               | 242                    | 1 (Ref.)               | 665                    | 1 (Ref.)               |
| Impaired fasting glucose | 875,575 | 1563                  | 0.98 (0.92,1.04)       | 62                        | 0.88 (0.65,1.19)       | 605                    | 1.00 (0.91,1.11)       | 440                    | 0.94 (0.84,1.06)       | 137                    | 1.06 (0.86,1.31)       | 377                    | 1.00 (0.88,1.13)       |
| Newly detected diabetes | 137,675 | 268                   | 1.02 (0.90,1.16)       | 12                        | 1.01 (0.56,1.83)       | 105                    | 1.05 (0.86,1.28)       | 78                     | 1.03 (0.82,1.30)       | 12                     | 0.57 (0.32,1.02)       | 67                     | 1.07 (0.83,1.38)       |
| Diabetes < 5 y | 150,114 | 389                   | 1.04 (0.94,1.16)       | 20                        | 1.30 (0.81,2.09)       | 145                    | 1.02 (0.86,1.23)       | 114                    | 1.12 (0.92,1.37)       | 31                     | 1.10 (0.76,1.61)       | 99                     | 0.99 (0.80,1.23)       |
| Diabetes ≥ 5 y | 114,271 | 352                   | 1.07 (0.96,1.20)       | 15                        | 1.17 (0.68,2.01)       | 142                    | 1.15 (0.96,1.37)       | 97                     | 1.13 (0.91,1.40)       | 21                     | 0.88 (0.56,1.39)       | 88                     | 0.94 (0.75,1.18)       |

#p for interaction

aHR; adjusted hazard ratio; confidence interval. The analysis models were adjusted for age, sex, smoking, drinking, physical activity, and body mass index.
4. Discussion

To our knowledge, this is the first study that investigated the risk of a wide range of hematologic malignancies according to the broad diabetic spectrum, such as normal glucose tolerance, prediabetes, and diabetes with shorter and longer durations after a robust adjustment for potential confounders, including the BMI. This large-scale nationwide population-based cohort study revealed an increasing trend of the risk of all hematologic malignancies and NHL according to the progression of the glycemic status toward diabetes with a longer disease duration, without a significant interaction with obesity.

The present study suggested that the risk of NHL was linearly and positively associated with the progression of the glycemic status toward diabetes with a longer disease duration. This finding was consistent with a previous study [20], in which participants with diabetes for >3.5 years had a higher risk for NHL (aHR 1.17 95% CI 1.03–1.33) than those with diabetes ≤ 3.5 years did (who had no increased risk of NHL, aHR 0.94 95% CI 0.82–1.08) [9]. An Israeliite study showed that the highest risk of NHL was in the first year of a diabetes diagnosis (aHR 5.53 95% CI 5.01–6.10) and no significant association in the following year (aHR 1.24 95% CI 0.98–1.58 in 1 to 2 years after the diagnosis) and, again, an increased risk in the subsequent years (aHR 1.41 95% CI 1.25–1.59 in 2–11 years) [12]. The highest risk of NHL in the first year of a diabetes diagnosis in the study of Israeliite might be due to a further diagnostic work-up and frequent healthcare contacts immediately after the diagnosis of diabetes. However, our analysis avoided surveillance bias, because we compared the risk of NHL using the baseline glycemic status of each participant of the national health screening program. In addition, our sensitivity analyses without a 1-year lag period did not find a higher risk in the first year of a diabetes diagnosis.

The current study showed an increased incidence of HL among people with diabetes, when compared to those without diabetes. However, it turned out to be attributable to the increased incidence of HL among people with diabetes with a shorter duration, failing to show an increasing trend of the risk of HL according to the progression of glycemic status toward diabetes with a longer disease duration. An earlier meta-analysis reported no association between diabetes and HL [8]. Other studies have also failed to show a significant association between diabetes and incident HL [5–7]. Given the low incidence of HL, which is around one-tenth of NHL [21], and that the majority of HL occurs before age 40, the age distribution of a study population is very important to detect a significant difference in the risk of HL in relation to diabetes. However, most previous studies, including one large-scale Australian study, only included participants aged > 40 years [3,6,14]. Therefore, it is difficult to find evident differences regarding the HL risk between patients with and without diabetes. In contrast, our study included a large number of participants with <40 (N = 3,099,268) years of age and provided an improved power to test the relationship between diabetes and HL. In addition, unlike in Western countries where there is a bimodal incidence pattern of HL, the peak incidence of HL in Korea is 19–30 years [22]. We speculate that the overall increase in the incidence of HL in those with diabetes in the present study should be confirmed by further studies and meta-analyses, including a sufficient number of participants <40 years of age, with consideration of the baseline glucose tolerance status and diabetes duration.

Our study found no significant association between diabetes and the risk of other specific hematologic malignancies, such as ML, LL, and MM. Although there was a small but significant association between the diabetes ≥ 5 year group and the risk of ML in the participants with ages < 40 years, it was difficult to draw a conclusion because of the small event number. Two studies from in Italy and England also both reported that diabetes was not associated with an elevated risk of LL [11,14]. In addition, although the risk of ML and LL were not presented separately, the overall risk of leukemia among the individuals with diabetes was not different from that of the general population in Taiwan [9]. A meta-analysis showed no significant association between diabetes and MM (OR 1.22, 95% CI 0.98–1.53) [8], which was consistent with our findings.
Several possible mechanisms have been proposed regarding the association between diabetes and hematologic malignancies. First, chronic exposure to hyperinsulinemia plays an important role in tumor development and progression by modulating insulin-like growth factor-1 (IGF-1) activity. Insulin inhibits the production of IGF-1-binding proteins from the liver [23], which leads to an increased concentration of biologically active free IGF-1, which is involved in tumor promotion. Second, increased insulin levels can trigger the IGF-1 signaling pathway that subsequently activates phosphoinositide 3 kinase (PI3K) and mitogen-activated protein kinase (MAPK). These two kinases ultimately influence the cell survival and tumor development [24,25]. This hypothesis was partly supported by a recent prospective epidemiologic study, which found a positive tendency between plasma IGF-1 and diffuse larger B-cell lymphoma, although a statistical significance was not reached [26]. Second, the microangiopathy of the bone marrow niche in diabetes could be attributable to the risk of hematologic malignancies. An experimental study of mice demonstrated that the bone marrow of mice with diabetes showed a more fragmented microvascular structure and reduced cellularity and perfusion compared with the bone marrow of the control [27]. Third, diabetes is accompanied frequently by hyperleptinemia as a result of leptin resistance, and leptin signaling could participate in the pathogenesis of hematologic malignancy. A complex interplay among obesity, fat mass, adipokines, and the risk of hematologic malignancy has been suggested [28,29]. In addition, oxidative stress, which is associated with chronic inflammation, might promote the development of hematologic malignancies. Several biomarkers such as malondialdehyde, superoxide anion, and $H_2O_2$ were elevated in hematologic malignancies. These biomarkers imply that oxidative stress contributes to the development of these malignancies [30].

Notably, the BMI did not affect the association between diabetes and the risk of hematologic malignancies in our study. Since people with diabetes in East Asia have a lower mean BMI than those in more Western countries [31], we had the statistical power to determine if the risk of hematologic malignancy is equally increased in lean people with diabetes than it is in patients with higher BMIs. Our study demonstrated that the risks of HL and NHL were consistently increased even in people with diabetes with normal BMIs. This finding implies that the pathophysiologic link between diabetes and hematologic malignancy may not be confined to insulin resistance. For example, oxidative stress related to hyperglycemia and glycemic variability could at least, in part, play a contributory role in the development of NHL [30].

This study had several limitations that should be noted. First, we had limited information on the dietary patterns [32] and viral infections, such as human T-cell lymphotropic virus 1, Epstein–Barr virus, and human herpes-virus 8 infection [33,34]. Second, we did not consider the potential role of anti-diabetes medications in the development of hematologic malignancies, because the main focus of this study was to investigate the diabetes duration and hematologic malignancies. Third, because the younger age group (20–40 years) was only composed of employed individuals, the issue of under-representativeness could be raised in this age group. Differences in sociodemographic and health profiles between unemployed and employed groups might have an influence on the observed association in the younger group. Fourth, 5.2% of the eligible participants ($N = 547,526$) were excluded from the analyses due to missing information (mainly on smoking, alcohol consumption, and physical activity). The participants with missing information tended to be younger (45.5 vs. 47.2 years) and were more likely to be male (63.2% vs. 54.8%). However, after adjusting for age and sex, there was no difference in the risk of hematologic malignancies between participants with and without missing variables (HR1.06, 95% CI: 0.99–1.13). Furthermore, most of the missing information was alcohol consumption, smoking status, and physical activity; hence, it is unlikely that there was a significant bias in the present study. Fifth, the risk of the NHL subtypes was not estimated due to a lack of detailed information on the pathologic findings. Sixth, our results may not be generalizable to other populations, considering that hematological cancers have different epidemiological patterns and risk profiles across geographic regions and ethnicities [33].
5. Conclusions

In conclusion, this large population-based nationally representative study in Korea demonstrated diabetes to be associated with an increased risk of overall hematologic malignancies independent of obesity. The risk of NHL increased according to the progression of dysglycemia toward diabetes with a longer disease duration, while HL did not.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/cancers13194760/s1, Figure S1. Cumulative incidence of overall hematologic malignancy, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma in newly detected diabetes. HL, Hodgkin’s lymphoma; NHL, non-Hodgkin’s lymphoma, Table S1. Sensitivity analysis of the association between diabetes and risk of hematologic malignancies without 1-year lag period, Table S2. The risk of hematologic malignancies according to glycemic status and diabetes duration without 1-year lag period, Table S3. Subgroup analysis of association of the risk of hematologic malignancies in diabetes patients ac-counting for diabetes medications.

Author Contributions: J.K., S.-M.J. (Sang-Man Jin) and D.W.S. designed the research; J.K., S.-M.J. (Sang-Man Jin), S.J.K., D.K., K.H., S.-M.J. (Su-Min Jeong), J.C., S.Y.R., T.C. and D.W.S. performed the research; D.K., K.H., T.C. and D.W.S. contributed vital analytical tools; J.K., S.-M.J. (Sang-Man Jin), D.K., K.H., T.C. and D.W.S. analyzed the data; and J.K., S.J.K. and D.W.S. wrote the paper. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: This study’s protocol was approved by the Institutional Review Board of the Samsung Medical Center (SMC 2018-08-112). Informed consent was waived, because anonymized and deidentified data were used.

Informed Consent Statement: Not required due to the study design. Informed consent from individual participants was waived, as this study involved only deidentified data.

Data Availability Statement: The data that support the findings of this study are available from the National Health Insurance Corporation, but restrictions apply to the availability of these data, which were used under license NHIS-2019-1-130 for the current study and are not publically available. The data are, however, available from the authors upon reasonable request and with permission of the National Health Insurance Corporation.

Acknowledgments: This study was performed using the database from the National Health Insurance System (NHIS-2019-1-130), and the results do not necessarily represent the opinion of the National Health Insurance Corporation.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. El-Serag, H.B.; Tran, T.; Everhart, J.E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. *Gastroenterology* 2004, 126, 460–468. [CrossRef] [PubMed]
2. Friberg, E.; Orsini, N.; Mantzoros, C.S.; Wolk, A. Diabetes mellitus and risk of endometrial cancer: A meta-analysis. *Diabetologia* 2007, 50, 1365–1374. [CrossRef] [PubMed]
3. Harding, J.L.; Shaw, J.E.; Peeters, A.; Cartensen, B.; Magliano, D.J. Cancer risk among people with type 1 and type 2 diabetes: Disentangling true associations, detection bias, and reverse causation. *Diabetes Care* 2014, 38, 264–270. [CrossRef]
4. Jiang, Y.; Ben, Q.; Shen, H.; Lu, W.; Zhang, Y.; Zhu, J. Diabetes mellitus and incidence and mortality of colorectal cancer: A systematic review and meta-analysis of cohort studies. *Eur. J. Epidemiol.* 2011, 26, 863–876. [CrossRef] [PubMed]
5. Atchison, E.; Gridley, G.; Carreon, J.D.; Leitzmann, M.F.; McGlynn, K.A. Risk of cancer in a large cohort of U.S. veterans with diabetes. *Int. J. Cancer* 2010, 128, 452–459. [CrossRef] [PubMed]
6. Lai, G.Y.; Park, Y.; Hartge, P.; Hollenbeck, A.R.; Freedman, N.D. The association between self-reported diabetes and cancer incidence in the NIH-AARP diet and health study. *J. Clin. Endocrinol. Metab.* 2013, 98, E497–E502. [CrossRef] [PubMed]
7. Saarela, K.; Tuomilehto, J.; Sund, R.; Keskimäki, I.; Hartikainen, S.; Pukkala, E. Cancer incidence among Finnish people with type 2 diabetes during 1989–2014. *Eur. J. Epidemiol.* 2018, 34, 259–265. [CrossRef] [PubMed]
8. Castillo, J.J.; Mull, N.; Reagan, J.L.; Nemr, S.; Mitri, J. Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: A meta-analysis of observational studies. *J. Am. Soc. Hematol.* 2012, 119, 4845–4850. [CrossRef] [PubMed]
9. Lo, S.-F.; Chang, S.-N.; Muo, C.-H.; Chen, S.-Y.; Liao, F.-Y.; Dee, S.-W.; Chen, P.-C.; Sung, F.-C. Modest increase in risk of specific types of cancer in type 2 diabetes mellitus patients. *Int. J. Cancer* 2012, 132, 182–188. [CrossRef] [PubMed]
10. Hu, Y.; Zhang, X.; Ma, Y.; Yuan, C.; Wang, M.; Wu, K.; Tabung, F.K.; Tobias, D.; Hu, F.B.; Giovannucci, E.; et al. Incident type 2 diabetes duration and cancer risk: A prospective study in two US cohorts. *J. Natl. Cancer Inst.* 2020, 113, 381–389. [CrossRef]

11. Wotton, C.J.; Yeates, D.G.R.; Goldacre, M.J. Cancer in patients admitted to hospital with diabetes mellitus aged 30 years and over: Record linkage studies. *Diabetologia* 2010, 54, 527–534. [CrossRef]

12. Dankner, R.; Hoffe, P.; Balicer, R.D.; Boker, L.K.; Sadeh, M.; Berlin, A.; Olmer, L.; Goldfracht, M.; Freedman, L.S. Time-Dependent Risk of Cancer After a Diabetes Diagnosis in a Cohort of 2.3 Million Adults. *Am. J. Epidemiol.* 2016, 183, 1098–1106. [CrossRef]

13. Yang, W.-S.; Li, H.-L.; Xu, H.-L.; Yang, G.; Gao, Y.-T.; Zheng, W.; Shu, X.-O.; Xiang, Y.-B. Type 2 diabetes and the risk of non-Hodgkin’s lymphoma: A report from two population-based cohort studies in China. *Eur. J. Cancer Prev.* 2016, 25, 149. [CrossRef] [PubMed]

14. Gini, A.; Bidoli, E.; Zanier, L.; Clagnan, E.; Zanette, G.; Gobbato, M.; De Paoli, P.; Serraino, D. Cancer among patients with type 2 diabetes mellitus: A population-based cohort study in northeastern Italy. *Cancer Epidemiol.* 2016, 41, 80–87. [CrossRef] [PubMed]

15. Tseng, C.-H. Diabetes and non-Hodgkin’s lymphoma: Analyses of prevalence and annual incidence in 2005 using the national health insurance database in Taiwan. *Ann. Oncol.* 2011, 23, 153–158. [CrossRef]

16. Khan, A.E.; Gallo, V.; Linseisen, J.; Kaaks, R.; Rohrmann, S.; Raaschou-Nielsen, O.; Tjønneland, A.; Johnsen, H.E.; Overvad, K.; Bergmann, M.M.; et al. Diabetes and the risk of non-Hodgkin’s lymphoma and multiple myeloma in the European Prospective Investigation into Cancer and Nutrition. *Haematologica* 2008, 93, 842–850. [CrossRef] [PubMed]

17. American Diabetes Association. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2020. *Diabetes Care* 2020, 43, S14. [CrossRef] [PubMed]

18. Rhee, S.Y.; Han, K.-D.; Kwon, H.; Park, S.-E.; Park, Y.-G.; Kim, Y.-H.; Yoo, S.-J.; Rhee, E.-J.; Lee, W.-Y. Association between glycemic status and the risk of parkinson disease: A nationwide population-based study. *Diabetes Care* 2020, 43, 2169–2175. [CrossRef] [PubMed]

19. Jeong, S.-M.; Choi, T.; Kim, D.; Han, K.; Kim, S.J.; Rhee, S.Y.; Giovannucci, E.L.; Shin, D.W. Association between high-density lipoprotein cholesterol level and risk of hematologic malignancy. *Leukemia* 2020, 35, 1–9. [CrossRef]

20. Cerhan, J.R.; Wallace, R.B.; Lutz, C.T.; Folsom, A.R.; Thomas, A.S.; Zheng, W.; Potter, J.D. Medical history risk factors for non-Hodgkin’s lymphoma in older women. *J. Natl. Cancer Inst.* 1997, 89, 314–318. [CrossRef] [PubMed]

21. Hong, S.; Won, Y.-J.; Park, Y.R.; Jung, K.-W.; Hong, H.-J.; Lee, E.S. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in cancer research and treatment. *Off. J. Korean Cancer Assoc.* 2020, 52, 335.

22. Won, Y.-W.; Kwon, J.H.; Lee, S.I.; Oh, S.Y.; Kim, W.S.; Kim, S.J.; Won, J.-H.; Kim, K.H.; Park, S.K.; Kim, J.S.; et al. Clinical features and outcomes of Hodgkin’s lymphoma in Korea: Consortium for Improving survival of lymphoma (CISL). *Ann. Hematol.* 2011, 91, 223–233. [CrossRef]

23. Böni-Schnetzler, M.; Schmid, C.; Mary, J.-L.; Zimmerli, B.; Meier, P.J.; Zapf, J.; Schwander, J.; Froesch, E.R. Insulin regulates the expression of the insulin-like growth factor binding protein 2 mRNA in rat hepatocytes. *Mol. Endocrinol.* 1990, 4, 1320–1326. [CrossRef] [PubMed]

24. Lawlor, M.A.; Alessi, D.R. PKB/Akt: A key mediator of cell proliferation, survival and insulin responses? *J. Cell Sci.* 2001, 114, 2903–2910. [CrossRef] [PubMed]

25. Weijzen, S.; Velders, M.; Kast, W. Modulation of the immune response and tumor growth by activated Ras. *Leukemia* 1999, 13, 502–513. [CrossRef]

26. Perez-Cornago, A.; Appleby, P.N.; Tipper, S.; Key, T.J.; Allen, N.E.; Nieters, A.; Vermeulen, R.; Roulard, S.; Casabonne, D.; Kaaks, R. Prediagnostic circulating concentrations of plasma insulin-like growth factor-I and risk of lymphoma in the European prospective investigation into cancer and nutrition. *Int. J. Cancer* 2017, 140, 1110–1118. [CrossRef]

27. Oikawa, A.; Siragusa, M.; Quaini, F.; Mangialardi, G.; Katari, R.; Caporali, A.; Van Buul, J.; Van Alphen, F.P.; Graiani, G.; Spinetti, G.; et al. Diabetes mellitus induces bone marrow microangiopathy. *Arterioscler. Thromb. Vasc. Biol.* 2010, 30, 498–508. [CrossRef] [PubMed]

28. Kraakman, M.J.; Kammoun, H.L.; Dragoljevic, D.; Al-Sharea, A.; Lee, M.K.; Flynn, M.C.; Stolz, C.J.; Guirguis, A.A.; Lancaster, G.I.; Chin-Dusting, J.; et al. Leptin-deficient obesity prolongs survival in a murine model of myelodysplastic syndrome. *Haematologica* 2018, 103, 597–606. [CrossRef] [PubMed]

29. Han, T.-J.; Wang, X. Leptin and its receptor in hematologic malignancies. *Int. J. Clin. Exp. Med.* 2015, 8, 19840. [PubMed]

30. Imbesi, S.; Musolino, C.; Allegra, A.; Saita, A.; Morabito, F.; Calapai, G.; Gargemini, S. Oxidative stress in oncohematologic diseases: An update. *Expert Rev. Hematol.* 2013, 6, 317–325. [CrossRef]

31. Ma, R.C.; Chan, J. Type 2 diabetes in East Asians: Similarities and differences with populations in Europe and the United States. *Ann. NY Acad. Sci.* 2013, 1281, 64–91. [CrossRef] [PubMed]

32. Wang, Y.; Liu, X.; Yan, P.; Bi, Y.; Liu, Y.; Zhang, Z.-J. Association between type 1 and type 2 diabetes and risk of non-Hodgkin’s lymphoma: A meta-analysis of cohort studies. *Diabetes Metab.* 2020, 46, 8–19. [CrossRef] [PubMed]

33. Cook, L.; Melamed, A.; Niederer, H.; Valgonan, M.; Laydon, D.; Foroni, L.; Taylor, G.P.; Matsuoka, M.; Bangham, C.R.M. The role of HTLV-1 clonality, proviral structure, and genomic integration site in adult T-cell leukemia/lymphoma. *Blood* 2014, 123, 3925–3931. [CrossRef]

34. Fassone, L.; Bhatia, K.; Gutierrez, M.; Capello, D.; Coglioni, A.; Dolcetti, R.; Vivenzia, D.; Ascoli, V.; Coco, F.; Pagani, L.; et al. Molecular profile of Epstein–Barr virus infection in HHV-8-positive primary effusion lymphoma. *Leukemia* 2000, 14, 271–277. [CrossRef] [PubMed]